跳至主要内容
临床试验/NCT03104621
NCT03104621已完成4 期

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

Gangnam Severance Hospital0 个研究点目标入组 20 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
20
主要终点
The change of corneal erosion grade by preservative free 0.0015% tafluprost

研究概览

简要总结

The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost. Both preservative containing and preservative-free 0.0015% tafluprost will reduce intraocular pressure significantly. In addition, preservative-free 0.0015% tafluprost might improve tolerability of glaucoma patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Investigators, patients and other study participants were blinded to treatment assignment throughout the study. Evaluator of IOP was also masked to treatment assignment.

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary open angle glaucoma and normotensive glaucoma patients who came to the outpatient clinic for regular glaucoma check-ups were enrolled.
  • Glaucoma was defined as the patients who had open angle confirmed by gonioscopy, optic nerve cupping (a vertical cup-disc ratio of >0.6) and or notching of the neuroretinal rim and or retinal nerve fiber defects characteristics of glaucoma, and visual field defect(i.e., a glaucoma hemi-filed test result outside normal limits, a pattern standard deviation probability of <5%, or a cluster of three or more non-edge points in location typical of glaucoma, all of which were depressed on a pattern deviation plot at a P level of <5%, and at least one of which was depressed at a P level of <1% on two consecutive visual field tests).
  • Normal tension glaucoma included criteria: repeated measurements of untreated IOP values of < 21mmHg. Primary open angle glaucoma included criteria: repeated measurements of untreated IOP values of ≥ 22mmHg.

排除标准

  • Phakic and pseudophakic eyes.
  • eyes that had been taken vitrectomy, trabeculectomy, or surgery influenced IOP

研究组 & 干预措施

Group 1

Experimental

Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.

干预措施: Benzalkonium chloride (BAK) (Drug)

Group 1

Experimental

Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.

干预措施: 0.0015% tafluprost (Drug)

Group 2

Experimental

Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.

干预措施: Benzalkonium chloride (BAK) (Drug)

Group 2

Experimental

Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.

干预措施: 0.0015% tafluprost (Drug)

结局指标

主要结局

The change of corneal erosion grade by preservative free 0.0015% tafluprost

时间窗: after 1, 3, and 6 months using drug in group 1/ after 7, 9, and 12 months using drug in group 2

Corneal erosion scales were scored according to the area of erosion. Little to no erosion was "0", erosion on 1/3 of the area of the entire cornea was "1", erosion on 2/3 of the area of the entire cornea was "2", and erosion on the entire cornea was "3"

The change of tear break up time by preservative free 0.0015% tafluprost

时间窗: after 1, 3, and 6 months using drug in group 1/ after 7, 9, and 12 months using drug in group 2

Tear breakup time was checked by slit lamp exam under corneal fluorescein dye. We asked patients not to blink, and the time was counted until tear film was torn apart (seconds)

The change of tear break up time by preservative contained 0.0015% tafluprost

时间窗: after 1, 3, and 6 months using drug in group 2/ after 7, 9, and 12 months using drug in group 1

Tear breakup time was checked by slit lamp exam under corneal fluorescein dye. We asked patients not to blink, and the time was counted until tear film was torn apart (seconds)

The change of Schirmer test by preservative contained 0.0015% tafluprost

时间窗: after 1, 3, and 6 months using drug in group 2/ after 7, 9, and 12 months using drug in group 1

or tear secretion, schirmer test paper was placed into the conjunctival sac at the point of 1/3 from lateral canthus under topical anaesthesia (5% Proparacaine HCl, Alcaine®, Alcon Laboratories Inc., TX, USA). After 5 minutes, we checked the wet height with tear (mm)

The change of Schirmer test by preservative free 0.0015% tafluprost

时间窗: after 1, 3, and 6 months using drug in group 1/ after 7, 9, and 12 months using drug in group 2

For tear secretion, schirmer test paper was placed into the conjunctival sac at the point of 1/3 from lateral canthus under topical anaesthesia (5% Proparacaine HCl, Alcaine®, Alcon Laboratories Inc., TX, USA). After 5 minutes, we checked the wet height with tear (mm)

The change of corneal erosion grade by preservative contained 0.0015% tafluprost

时间窗: after 1, 3, and 6 months using drug in group 2/ after 7, 9, and 12 months using drug in group 1

Corneal erosion scales were scored according to the area of erosion. Little to no erosion was "0", erosion on 1/3 of the area of the entire cornea was "1", erosion on 2/3 of the area of the entire cornea was "2", and erosion on the entire cornea was "3"

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gong Je Seong

Associate Professor

Gangnam Severance Hospital

相似试验

进行中(未招募)
不适用
Evaluation of tolerance and efficacy of preparation TERBINAFIN HBF CREAM (Herbacos-Bofarma) and its comparison with preparation LAMISIL CREAM (Novartis) in patients with interdigital form of tinea pedis.
EUCTR2005-000940-10-CZRE&D VÚFB, s.r.o.140
未知
3 期
To Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
JPRN-jRCT2080222381AbbVie GK32
招募中
2 期
Evaluation of the tolerability of sustained-release morphine for patients with interstitial lung diseaseinterstitial pneumonia
JPRN-jRCTs041230028Suda Takafumi34
进行中(未招募)
1 期
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2015-004098-33-DKBiogen Idec Research Limited183
进行中(未招募)
1 期
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral Sclerosis (ALS)MedDRA version: 20.0Level: PTClassification code 10077024Term: Familial amyotrophic lateral sclerosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2015-004098-33-PLBiogen Idec Research Limited183